$700m injury payout headed to Zyprexa users

Share this article:
A federal judge approved Eli Lilly’s largest-ever settlement: $700 million to be split among patients who took antipsychotic Zyprexa, their lawyers and federal health programs, The Indianapolis Star reported. Judge Jack Weinstein, of federal court in Brooklyn, NY, approved the terms of the liability settlement, but the amount could expand. Hundreds more have filed claims against Lilly since the settlement was announced in 2005, according to The Star. So far, more than 8,000 plaintiffs, many of them mentally ill, are included. They will receive payments after attorneys, Medicare and Medicaid get their cut. More than 60% of claimants were Medicaid beneficiaries, and some states reportedly could claim up to 30% of each award from people who have health coverage through the state-run plans. After taking Zyprexa, Lilly’s top seller, the patients claimed that the drug caused diabetes-related symptoms, including weight gain and high blood-sugar levels.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...